DermTech, Inc.DMTK

NASDAQHealthcareBiotechnology$0.09-11.32%

Price as of Sep 10, 4:54 PM EDT · delayed, not real-time

Specializing in non-invasive genomics tests for skin cancer detection, this company develops diagnostic tools that reduce the need for surgical biopsies. Its flagship product, the Pigmented Lesion Assay, targets early melanoma detection, a key focus area for healthcare cost reduction. Investors monitor DermTech for its potential to disrupt traditional dermatologic diagnostics despite its micro-cap status.

Market Cap: $3.3M52W Range: $0.04-$3.90

Congressional Interest in DermTech, Inc. (DMTK)

1 member of Congress has disclosed 3 trades in DermTech, Inc. (DMTK), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 1 sale, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.